Researchers find that influenza has an Achilles' heel

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study published by Cell Press on April 10 in the journal Immunity reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus. The findings pave the way for an urgently needed therapy that is highly effective against the flu virus and potentially other viral infections.

"Drugs that specifically target PGE2 pathways have already been developed and tested in animals, so our results have excellent potential for clinical translation, not only for the treatment of influenza, but also other that interact with similar host immune pathways," says senior study author Maziar Divangahi of McGill University.

Despite the worldwide use of vaccination and other antiviral interventions, the remains a persistent threat to human health. To investigate molecular pathways that could be targeted by novel interventions, Divangahi and his team became interested in ibuprofen, which is commonly used to manage flu-like symptoms. By inhibiting a molecule called cyclooxygenase (COX), ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) lower the production of prostaglandins—immune molecules that contribute to pain and fever. But COX inhibition has produced conflicting effects on immune responses and survival rates in animals infected with the flu virus, highlighting the importance of clarifying the role of prostaglandins in antiviral immunity.

In the new study, Divangahi and his team found that mice genetically engineered to lack PGE2 showed enhanced immune responses, lower viral levels in the lungs, and better survival rates following infection with a of the H1N1 flu virus compared with infected mice that were not genetically modified. Similarly, mice treated with a compound that inhibits PGE2 showed enhanced antiviral immunity and following infection with a lethal dose of the flu virus compared with untreated mice.

"We believe that previous studies produced conflicting results because COX inhibition affects all prostaglandins, not just PGE2," Divangahi says. "Our findings suggest that different prostaglandins have different roles in and that specific inhibition of PGE2 will be much more effective than NSAIDs at protecting against influenza infection."

More information: Immunity, Coulombe et al.: "Targeted Prostaglandin E2 Inhibition Enhances Anti-Viral Immunity through Induction of Type I Interferon and Apoptosis in Macrophages." dx.doi.org/10.1016/j.immuni.2014.02.013

add to favorites email to friend print save as pdf

Related Stories

Fatty acids could lead to flu drug

Mar 07, 2013

Flu viruses are a major cause of death and sickness around the world, and antiviral drugs currently do not protect the most seriously ill patients. A study published March 7th by Cell Press in the journal Cell reveals that a ...

The rocky road to a better flu vaccine

Jan 23, 2014

Currently approved flu vaccines are less effective in the elderly, yet an estimated 90% of influenza-related deaths occur in people over 65. A paper published on January 23rd in PLOS Pathogens reports on the ...

Recommended for you

Study unlocks basis of key immune protein's two-faced role

Nov 26, 2014

A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system—sometimes dampening it, other times stimulating ...

Profilin can induce severe food-allergic reactions

Nov 25, 2014

(HealthDay)—Profilins are complete food allergens in food-allergic patient populations that are exposed to high levels of grass pollen, according to a study published in the December issue of Allergy.

Structured education program beneficial for anaphylaxis

Nov 21, 2014

(HealthDay)—A structured education intervention improves knowledge and emergency management for patients at risk for anaphylaxis and their caregivers, according to a study published online Nov. 19 in Allergy.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.